Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Cory Kasimov
EVR
Cory Kasimov
Evercore ISI
Wall Street Analyst
★★☆☆☆
#2134
on 13Foresight · ranked by our own returns
46%
Success Rate
-1.8%
Average Return
23 of 50 calls profitable · -134088.9% vs benchmark
📈 Across the calls we could measure, roughly 46% of Cory Kasimov's ratings turned a profit when each position was held for 1 year — averaging -1.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

113 Buy 10 Hold 0 Sell
Cory's Stock Coverage 51 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
COAG
Hemab Therapeutics Holdings, Inc.
 May 26, 2026 BUY Strong Buy
+41.6% avg upside
5 analysts
$50.00
70.95% Upside
 ·
BMRN
BioMarin Pharmaceutical
 May 21, 2026 BUY Strong Buy
+72.8% avg upside
52 analysts
$120.00
119.42% Upside
 +1.7%
REGN
Regeneron
 May 18, 2026 BUY Strong Buy
+26.9% avg upside
57 analysts
$825.00
35.17% Upside
 -3.3%
NBIX
Neurocrine
 May 18, 2026 BUY Strong Buy
+7.8% avg upside
37 analysts
$210.00
32.71% Upside
 +1.6%
IMNM
Immunome
 May 13, 2026 BUY Strong Buy
+83.0% avg upside
16 analysts
$40.00
113.38% Upside
 -16.5%
BNTC
Benitec Biopharma
 May 12, 2026 BUY Strong Buy
+118.1% avg upside
13 analysts
$25.00
105.67% Upside
 -3.0%
SRRK
Scholar Rock Holding
 May 08, 2026 BUY Strong Buy
+20.1% avg upside
23 analysts
$65.00
37.39% Upside
 -3.0%
EWTX
Edgewise Therapeutics
 May 08, 2026 BUY Strong Buy
+22.4% avg upside
14 analysts
$45.00
22.30% Upside
 -3.9%
BEAM
Beam Therapeutics
 May 08, 2026 BUY Strong Buy
+50.8% avg upside
25 analysts
$45.00
31.73% Upside
 +5.6%
BBIO
BridgeBio Pharma
 May 08, 2026 BUY Strong Buy
+38.7% avg upside
34 analysts
$130.00
96.18% Upside
 +0.0%
XENE
Xenon
 May 08, 2026 BUY Strong Buy
+19.0% avg upside
28 analysts
$80.00
51.15% Upside
 -7.2%
RVMD
Revolution Medicines
 May 07, 2026 BUY Strong Buy
-12.3% avg upside
32 analysts
$200.00
22.67% Upside
 +10.7%
VIR
Vir Biotechnology
 May 07, 2026 BUY Strong Buy
+185.4% avg upside
16 analysts
$18.00
96.43% Upside
 +0.3%
VRTX
Vertex Pharmaceuticals
 May 05, 2026 BUY Strong Buy
-2.6% avg upside
61 analysts
$535.00
18.38% Upside
 +8.2%
MRNA
Moderna
 May 04, 2026 HOLD Hold
+6.1% avg upside
38 analysts
$50.00
21.89% Downside
 +35.2%
SMMT
Summit Therapeutics
 May 01, 2026 BUY Strong Buy
+112.6% avg upside
27 analysts
$34.00
147.27% Upside
 -13.9%
ALNY
Alnylam Pharma
 May 01, 2026 BUY Strong Buy
+23.6% avg upside
51 analysts
$400.00
43.86% Upside
 -4.5%
ORIC
Oric Pharmaceuticals
 Apr 01, 2026 BUY Strong Buy
+180.3% avg upside
19 analysts
$25.00
194.46% Upside
 +10.6%
CYTK
Cytokinetics
 Apr 01, 2026 BUY Strong Buy
+8.9% avg upside
36 analysts
$80.00
1.56% Upside
 +18.6%
UPB
Upstream Bio, Inc.
 Mar 27, 2026 HOLD Strong Buy
+514.9% avg upside
9 analysts
$15.00
140.04% Upside
 -25.6%
ZBIO
Zenas BioPharma, Inc.
 Mar 17, 2026 BUY Strong Buy
+102.2% avg upside
11 analysts
$55.00
178.13% Upside
 -20.9%
BNTX
BioNTech SE
 Mar 11, 2026 BUY Strong Buy
+50.5% avg upside
26 analysts
$130.00
43.02% Upside
 +0.1%
RARE
Ultragenyx Pharmaceutical
 Jul 29, 2022 BUY Strong Buy
+142.1% avg upside
36 analysts
$128.00
366.54% Upside
 -19.1%
NVCR
NovoCure
 Jul 28, 2022 HOLD Strong Buy
+242.4% avg upside
11 analysts
$84.00
488.17% Upside
 -52.6%
ALKS
Alkermes
 Jul 27, 2022 HOLD Strong Buy
-17.6% avg upside
34 analysts
$33.00
26.61% Downside
 +8.8%
BIIB
Biogen
 Jul 20, 2022 HOLD Strong Buy
+25.1% avg upside
51 analysts
$221.00
12.42% Upside
 +32.4%
ACAD
ACADIA Pharmaceuticals
 Jun 21, 2022 HOLD Strong Buy
+65.9% avg upside
42 analysts
$19.00
12.19% Downside
 +85.2%
SANA
Sana Biotechnology
 May 10, 2022 HOLD Strong Buy
+214.8% avg upside
14 analysts
$11.00
249.16% Upside
 +5.5%
ALLO
Allogene Therapeutics
 May 05, 2022 HOLD Strong Buy
+662.1% avg upside
28 analysts
$20.00
900.00% Upside
 -28.6%
EDIT
Editas Medicine
 May 04, 2022 SELL Buy
+407.9% avg upside
33 analysts
$16.00
494.74% Upside
 +44.9%
AMGN
Amgen
 Apr 28, 2022 HOLD Buy
-11.6% avg upside
57 analysts
$227.00
32.80% Downside
 +3.9%
INCY
Incyte
 Feb 09, 2022 HOLD Buy
+1.0% avg upside
47 analysts
$86.00
12.36% Downside
 +19.0%
LEGN
Legend Biotech
 Nov 19, 2021 BUY Strong Buy
+140.3% avg upside
27 analysts
$61.00
118.39% Upside
 -5.7%
TH
Target Hospitality
 Jun 02, 2021 BUY Strong Buy
-28.6% avg upside
10 analysts
 — +65.8%
GILD
Gilead Sciences
 Apr 29, 2021 HOLD Strong Buy
-4.8% avg upside
66 analysts
$74.00
40.17% Downside
 -2.9%
PBYI
Puma Biotechnology
 Feb 25, 2021 SELL Buy
+458.2% avg upside
11 analysts
 — +78.6%
WFC
Wells Fargo
 Jul 15, 2020 SELL Buy
+0.9% avg upside
37 analysts
 — -80.0%
ST
Sensata
 Nov 13, 2019 BUY Buy
+0.9% avg upside
21 analysts
 — -11.1%
ATYR
aTyr Pharma
 Jun 26, 2018 SELL Buy
+2023.9% avg upside
17 analysts
 — +64.0%
MNKD
MannKind
 May 11, 2017 SELL Buy
+78.6% avg upside
22 analysts
 — -45.7%
LLY
Eli Lilly & Co
 Apr 11, 2017 BUY Strong Buy
-10.5% avg upside
47 analysts
$100.00
90.97% Downside
 -5.9%
TSE:BHC
Bausch Health Companies
 Dec 15, 2015 BUY Buy
+807.0% avg upside
29 analysts
$283.27
4211.58% Upside
 ·
SGMO
Sangamo Therapeutics
 Dec 02, 2015 BUY Buy
+5844.2% avg upside
16 analysts
$16.00
9069.00% Upside
 -65.8%
TCRT
Alaunos Therapeutics
 Oct 30, 2015 HOLD Buy
+604.3% avg upside
13 analysts
 — -52.4%
KPTI
Karyopharm Therapeutics
 Sep 02, 2015 BUY Strong Buy
+147.4% avg upside
18 analysts
$20.00
121.79% Upside
 -27.4%
NVAX
Novavax
 Aug 11, 2015 BUY Buy
+154.1% avg upside
20 analysts
$14.00
53.44% Upside
 -50.6%
IONS
Ionis Pharmaceuticals
 Jun 08, 2015 HOLD Strong Buy
+13.3% avg upside
43 analysts
$68.00
8.17% Downside
 -67.8%
JPM
JPMorgan Chase
 Jan 13, 2015 HOLD Strong Buy
-21.6% avg upside
46 analysts
 — +0.1%
BCRX
BioCryst
 Dec 09, 2014 BUY Strong Buy
+103.3% avg upside
24 analysts
$18.00
100.27% Upside
 -3.9%
INFIQ
Infinity Pharmaceuticals
 May 07, 2014 BUY Buy
+647142757.1% avg upside
8 analysts
$20.00
1999999900.09% Upside
 +43.4%
RIGL
Rigel
 Jun 04, 2013 HOLD Strong Buy
-27.5% avg upside
17 analysts
 — -12.9%
🔒 46 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Cory Kasimov — Frequently Asked Questions
How accurate are Cory Kasimov's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Cory's ratings were profitable over a one-year hold, with an average return of -2.1% per rating, or -9.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Cory ranked on 13Foresight?
Cory Kasimov is currently ranked #2134 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Cory cover?
Cory most recently has ratings on COAG, BMRN, REGN, NBIX, IMNM, BNTC, SRRK, EWTX, BEAM, BBIO, XENE, RVMD and 39 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.